In the Phase 2 trial, the titration schedule for the 12 mg group looked roughly like this: Weeks 14 at 2 mg, weeks 58 at 4 mg, weeks 912 at 6 mg, weeks 1316 at 8 mg, then 12 mg from week 17 onward
However, our investigation of the GH/IGF-1 somatotropic axis did not reveal major alterations in hormone production and signaling, challenging our initial hypothesis that semaglutides effects on growth might be mediated through disruption of this pathway
lower waist size, blood pressure, and cholesterol) compared with those taking a placebo
I think we are going to have a long term patient-doctor relationship. - Cor E., Portland, OR
Developed by Novo Nordisk, it is an analog of natural human GLP-1 hormone, intended to enhance insulin secretion and regulate blood sugar levels